Clinical Trial

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

Name: An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma — clinical trial record (NCT07344818)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma

Trial Details

NCT Number	NCT07344818
Lead Sponsor	Peking University People's Hospital Collaborators: Hebei Senlang Biotechnology Co., LTD
Conditions	R/R Aggressive B-cell Lymphoma
Enrollment	18 participants
Start Date	2026-01-07
Primary Completion	2027-03-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-15